| Schedule of liabilities to be presented on balance sheet at fair value |
| Schedule of liabilities to be presented on balance sheet at fair value | |
Fair Value | |
Fair Value Measurements at |
| | |
As of | |
December 31, 2025 |
| Description | |
December 31, 2025 | |
Using Fair Value Hierarchy |
| | |
| |
Level 1 | |
Level 2 | |
Level 3 |
| Conversion feature on convertible notes | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| | |
Fair Value | |
Fair Value Measurements at |
| | |
As of | |
March 31, 2026 |
| Description | |
March 31, 2026 | |
Using Fair Value Hierarchy |
| | |
| |
Level 1 | |
Level 2 | |
Level 3 |
| Conversion feature on convertible notes | |
$ | 240,000 | | |
$ | 240,000 | | |
$ | — | | |
$ | — | |
|
| Schedule of potentially- dilutive shares |
| Schedule of potentially- dilutive shares | |
March 31, 2026 | |
December 31,
2025 |
| Basic outstanding common stock | |
| 22,217,870,775 | | |
| 20,217,870,775 | |
| Series B preferred stock | |
| 150,000 | | |
| 150,000 | |
| Series C preferred stock | |
| 385,000 | | |
| 385,000 | |
| Series H preferred stock | |
| 1,000,000 | | |
| 1,000,000 | |
| Series I preferred stock | |
| 10,000,000,000 | | |
| 10,000,000,000 | |
| Convertible notes | |
| 631,288,109,671 | | |
| 623,636,065,729 | |
| Total | |
| 663,507,515,446 | | |
| 653,855,471,504 | |
|